Impact

What a small foundation has built, in numbers

Everything below is open access and refreshed daily. Figures are from the live data on 8 October 2026.

42peer-reviewed papers in the Research Library

628registered clinical trials tracked daily

546biomarker entries, each with a verbatim-quoted source

602therapeutic agents with graded evidence

125chronic-condition pages with targets, candidates and trials

32post-acute infection cohorts catalogued for biobanking

400+career publications by our directors

0pharmaceutical-industry funding

Where it shows up

Cited, used, reused

Our post-acute COVID vaccination syndrome work is cited by national advisory bodies. The tracker's datasets carry a citable DOI and an embed widget, so other sites and papers can build on them rather than re-collect them. Every page says where its data came from, so a sceptical reader can check any claim in one click.

What your support funds

Components, not overheads

The roadmap is built from components small enough that one grant or one group of donors can complete one. Costs are rough, and we publish what each contribution funded.

Component	What it delivers	Rough cost
Biomarker atlas, one condition	Literature-grounded marker set with directions, comparison groups and sources, plus the atlas page	€300–800 in compute and curation time
Open-access publication fee	One peer-reviewed paper free to read for everyone, forever	€1,500–3,000
Gene-target panel for ten conditions	Druggable targets and candidate compounds, graded, with trials linked	€1,000–2,000
DecenTrial (beta → release)	Decentralised trial builder with standardised intervention and biomarker packages	€15,000–25,000
Post-viral biobank, pilot	Standardised sample collection and clinical annotation for one cohort	€40,000–80,000
Keeping the lights on	Hosting, registries, daily pipelines and corrections for a year	€3,000–5,000

♥ Fund a component

For grants, partnerships or in-kind contributions, get in touch. For code and data, see Contribute.